Compare Intuit Inc. (INTU) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuit Inc. vs TG Therapeutics Inc — how do they compare? Intuit Inc. trades at $302.56 (market cap $81.21B), while TG Therapeutics Inc trades at $55.14 (market cap $8.16B). The key difference: Intuit Inc. is far larger — about 10× TG Therapeutics Inc's market cap, and Intuit Inc. pays a 1.82% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Intuit Inc. for 66 Days and TG Therapeutics Inc for 16 Days on average.
| INTU | TGTX | |
|---|---|---|
Market Cap | $81.21B | $8.16B |
Volume | 5,165,806 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $683.39 | $59.06 |
52-Week Low | $255.07 | $26.94 |
Typical Hold Time | 66 Days | 16 Days |
Enterprise Value | $82.43B | $8.37B |
Dividend Yield | 1.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuit (INTU) trades at $297.24, up 2.56% today, with strong fundamentals including 21.29% net income margin and consistent earnings beats. The stock shows bullish technical signals despite mixed moving averages, with key support at $293 and resistance at $300. Recent news highlights growth in QuickBooks monetization and AI initiatives, though overshadowed by multiple class action lawsuits filed in early September 2026.
Outlook remains positive with analyst consensus target of $379.68 (27.7% upside), supported by robust revenue growth and expanding margins. Key risks include legal overhang from securities litigation and competitive pressures in financial software. Institutional sentiment leans bullish with 60% buy ratings, but investors should monitor lawsuit developments and Q3 2026 earnings due soon.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
